Sobi to share new clinical data and research at EULAR 2025

"We are delighted that our continued advancements in treating rare disease, including those suffering with the most debilitating rheumatology conditions will be presented at this year's EULAR conference. Sobi's presentations will provide insights and treatment options for those working with patients with rheumatological conditions, providing them with the most up-to-date clinical data and approaches," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi.

"We are delighted that our continued advancements in treating rare disease, including those suffering with the most debilitating rheumatology conditions will be presented at this year's EULAR conference. Sobi's presentations will provide insights and treatment options for those working with patients with rheumatological conditions, providing them with the most up-to-date clinical data and approaches," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi.

"With several poster and oral presentations and a longer form symposium, we are proud to be able to show how research and collaboration can advance clinical practice – and we look forward to meeting and connecting with colleagues in Barcelona," Lydia Abad-Franch concluded.

Key data to be presented at EULAR 2025

 

 

 

Session date: Thursday 12 June

Session time: 10:30 - 12:00 CEST

Presentation time: 10:48 - 10:57 CEST

Location: Room 6.1

 

 

Session date: Friday 13 June

Session time: 12:00 – 13:30 CEST

Location: Poster Hall

 

 

Session date: Friday 13 June

Session time: 10:15 - 11:45 CEST

Location: Poster Hall

 

 

Session date: Friday 13 June

Session time: 14 :45 - 15 :45 CEST

Location: Poster Hall

 

 

Session date: Saturday 14 June

Session time: 10:15 -11:45 CEST

Presentation time: 10:29 - 10:36 CEST (4 mins + 2 mins Q&A)

Location: Poster Tour II

 

 

Session date: Saturday 14 June

Session time: 10:15 - 11:45 CEST

Presentation time: 10:43 - 10:50 CEST (4 mins + 2 mins Q&A)

Location: Poster Tour II

 

 

Session time: 17:30 - 18:30 CEST

Location: Fira de Barcelona, Room B4

 

About Gamifant^® (emapalumab)

Gamifant^® (emapalumab) is indicated for the treatment of adult and paediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.

About Macrophage activation syndrome (MAS)

Macrophage activation syndrome (MAS) is a potentially life-threatening complication of Still's disease characterised by interferon-gamma (IFNγ)–driven systemic hyperinflammation. More than one-third of patients inadequately respond to high-dose glucocorticoids. Emapalumab, an anti-IFNγ antibody, demonstrated efficacy and safety in a phase 2 pilot study in patients with MAS in Still's disease and an inadequate response to high-dose glucocorticoids.

About NASP, formerly SEL-212

NASP is a novel investigational medicine designed to reduce serum urate (SU) levels in people with uncontrolled gout, potentially reducing harmful tissue urate deposits which when left untreated can lead to debilitating gout flares and joint deformity. NASP is administered every 4-weeks as a sequential, two-component, infusion therapy consisting of tolerogenic nanoencapsulated sirolimus (NAS) which mitigates the formation of anti-drug antibodies (ADAs) and a uricase, pegadricase (P), which reduces serum uric acid. ADAs develop due to unwanted immune responses to biologic medicines, reducing their efficacy and tolerability, which remains an issue across multiple therapeutic modalities and disease states including uncontrolled gout.

About VONJO^® (pacritinib)

VONJO is a kinase inhibitor that is indicated in the US for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

About VEXAS

VEXAS syndrome is a disease that causes inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene of blood cells and acquired later in life. The condition is not genetically inherited.

About Sobi 

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at  sobi.com and LinkedIn.

Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-to-share-new-clinical-data-and-research-at-eular-2025,c4156162

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/sobi-to-share-new-clinical-data-and-research-at-eular-2025-302466843.html